Literature DB >> 2852918

Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-gamma treatment.

E H Fennie1, Y S Lie, M A Low, P Gribling, K P Anderson.   

Abstract

Efficacy of recombinant DNA-derived murine IFN-gamma was investigated in a murine model of cytomegalovirus infection. Treatment of 3-week-old Swiss Webster mice with murine IFN-gamma prior to infection with murine cytomegalovirus (MCMV) significantly reduced mortality due to MCMV infection. Efficacy was dose-dependent and was observed using either intraperitoneal or intramuscular injection as the route of administration. Two doses, one at 24 h and one at 4 h prior to MCMV infection, were required for optimum efficacy, and doses administered after MCMV infection had no apparent effect. Reduced infectious MCMV titers were observed in critical organs of IFN-gamma treated mice and histopathologic lesions induced by MCMV infection were in general less severe and resolved sooner than lesions in untreated mice. Results in this murine model of cytomegalovirus infection suggest that IFN-gamma treatment may be useful as prophylactic therapy for human cytomegalovirus infections when a high probability of exposure to the virus exists and consequences of infection may be severe.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2852918     DOI: 10.1016/0166-3542(88)90012-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  9 in total

1.  Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver.

Authors:  Joy Loh; Dortha T Chu; Andrew K O'Guin; Wayne M Yokoyama; Herbert W Virgin
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines.

Authors:  C Söderberg-Nauclér; K N Fish; J A Nelson
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

3.  Reduced expression of gamma interferon in serum and marked lymphoid depletion induced by Porphyromonas gingivalis increase murine morbidity and mortality due to cytomegalovirus infection.

Authors:  Jacob Stern; Ela Shai; Batia Zaks; Amal Halabi; Yael Houri-Haddad; Lior Shapira; Aaron Palmon
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections.

Authors:  M T Heise; H W Virgin
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

5.  Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.

Authors:  B L Haagmans; P H van der Meide; F S Stals; A J van den Eertwegh; E Claassen; C A Bruggeman; M C Horzinek; V E Schijns
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

6.  Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages.

Authors:  R M Presti; D L Popkin; M Connick; S Paetzold; H W Virgin
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

7.  Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains.

Authors:  Julia Proff; Charlotte U Brey; Armin Ensser; Wolfgang Holter; Manfred Lehner
Journal:  J Transl Med       Date:  2018-02-08       Impact factor: 8.440

8.  Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels.

Authors:  R M Presti; J L Pollock; A J Dal Canto; A K O'Guin; H W Virgin
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

9.  A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells.

Authors:  Charlotte U Brey; Julia Proff; Natascha Teufert; Benjamin Salzer; Johannes Brozy; Markus Münz; Jochen Pendzialek; Armin Ensser; Wolfgang Holter; Manfred Lehner
Journal:  Sci Rep       Date:  2018-11-28       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.